MetaCap

Maze Therapeutics Earnings

NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

31.37-1.06 (-3.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Maze Therapeutics earnings summary

In its most recent report on Nov 9, 2026 (Sep/2026), MAZE posted EPS of $-0.79 versus the $-0.78 consensus estimate, a negative surprise of 1.3%. Maze Therapeutics beat the consensus EPS estimate in 1 of the last 2 quarters, with a median surprise of +7.1%. Across the last 9 reports, MAZE shares moved an average of 6.9% (in either direction) in the first trading session after results, rising 5 times and falling 4 times.

Summary generated from market data by MetaCap's automated system. Methodology

MAZE earnings history

Maze Therapeutics reported EPS versus estimates
Report dateEPS est.EPS actualSurprisePrice reaction
Nov 9, 2026$-0.78$-0.79-1.3%-8.6%
Nov 5, 2026$-0.78$-0.66+15.4%+0.4%
Aug 11, 2026—$-0.76—+8.3%
May 12, 2026—$-0.45—+0.9%
Mar 25, 2026—$-0.47—-5.5%
Nov 6, 2025—$-0.66—+13.7%
Aug 12, 2025—$-0.77—-0.1%
May 14, 2025—$-1.15—+11.1%
Mar 31, 2025—$22.19—-13.7%

Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.

Related